These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3546560)

  • 1. [Chronic renal failure: present and future. Pathophysiology and metabolic abnormalities--uremic toxin, middle and large molecular substances].
    Gejyo F
    Nihon Naika Gakkai Zasshi; 1986 Nov; 75(11):1550-4. PubMed ID: 3546560
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta-2-microglobulin as a uremic toxin: the Japanese experience.
    Fujimori A
    Contrib Nephrol; 2011; 168():129-133. PubMed ID: 20938132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloidosis in patients with end-stage renal failure: uraemia associated or dialysis related?
    Davison AM
    Contrib Nephrol; 1995; 113():92-100. PubMed ID: 7712726
    [No Abstract]   [Full Text] [Related]  

  • 4. [Beta 2-microglobulin--its role in renal failure and hemodialysis therapy].
    Czyz W; Szepietowski T
    Postepy Hig Med Dosw; 1992; 46(2):209-38. PubMed ID: 1470582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The anticoagulant activity of the plasma ultrafiltrate as a possible criterion of uremic poisoning].
    Sukhanov VA; Chuzhinov SV; Koriakov IO; Zlokazov VB
    Ter Arkh; 1991; 63(6):68-71. PubMed ID: 1948752
    [No Abstract]   [Full Text] [Related]  

  • 6. Optical Method and Biochemical Source for the Assessment of the Middle-Molecule Uremic Toxin β2-Microglobulin in Spent Dialysate.
    Paats J; Adoberg A; Arund J; Fridolin I; Lauri K; Leis L; Luman M; Tanner R
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. beta 2-microglobulin and amyloidosis: who is at risk?
    Davison AM
    Nephrol Dial Transplant; 1995; 10 Suppl 10():48-51. PubMed ID: 8825433
    [No Abstract]   [Full Text] [Related]  

  • 8. [Middle molecules and the problem of endogenous intoxication in critical states of various etiologies].
    Vladyka AS; Levitskiĭ ER; Poddubnaia LP; Gabriélian NI
    Anesteziol Reanimatol; 1987; (2):37-42. PubMed ID: 3300433
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pathogenesis of dialysis amyloidosis].
    Gejyo F; Hasegawa S; Homma N; Maruyama H; Maruyama S; Arakawa M
    Nihon Rinsho; 1992 Jan; 50 Suppl():796-800. PubMed ID: 1578769
    [No Abstract]   [Full Text] [Related]  

  • 10. [Long-term management of dialysis patients. II. Beta 2-microglobulin associated amyloidosis and acquired cystic kidney disease].
    Floege J; Segerer S; Schäffer J; Koch KM
    Internist (Berl); 1999 Jan; 40(1):64-9. PubMed ID: 10086302
    [No Abstract]   [Full Text] [Related]  

  • 11. [Middle-molecule uremic toxins: A renewed interest].
    Nlandu Y; Padden M; Seidowsky A; Hamaz S; Vilaine É; Cheddani L; Essig M; Massy ZA
    Nephrol Ther; 2019 Apr; 15(2):82-90. PubMed ID: 30954165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-2-microglobulin amyloidosis and osteo-articular pathology of the uremic patient on regular dialysis.
    Brancaccio D; Anelli A; Gallieni M; Padovese P; Coggi G; Uslenghi C
    Contrib Nephrol; 1990; 77():177-86. PubMed ID: 2188786
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum beta2-microglobulin in hemodialyzed patients.
    Vincent C; Revillard JP; Galland M; Traeger J
    Nephron; 1978; 21(5):260-8. PubMed ID: 82208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of uremic peaks by high performance liquid chromatography and their behavior].
    Koide K; Toyama J; Inoue N; Koshikawa S; Akizawa T; Takahashi K; Hidaka S; Yamane Y; Nakao M; Uehara Y
    Nihon Jinzo Gakkai Shi; 1986 Aug; 28(8):1101-10. PubMed ID: 3807043
    [No Abstract]   [Full Text] [Related]  

  • 15. [Changes in the picture of chronic diseases on long-term hemodialysis treatment].
    von Appen K; Ivanovich P; Klinkmann H; Stetsiuk E
    Urol Nefrol (Mosk); 1995; (5):25-7. PubMed ID: 8571479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dialysis-related amyloidosis].
    Nakazima Y; Akizawa T; Koshikawa S
    Nihon Rinsho; 1992 Jan; 50 Suppl():807-16. PubMed ID: 1578771
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β
    Yamamoto S
    Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-2-microglobulin: a possible new uremic toxin?
    Gejyo F; Brancaccio D
    Int J Artif Organs; 1988 Jan; 11(1):3-5. PubMed ID: 3283056
    [No Abstract]   [Full Text] [Related]  

  • 19. [Amyloidosis of the dialysis patient].
    van Ypersele de Strihou C
    Bull Mem Acad R Med Belg; 1988; 143(10-12):456-65; discussion 465-7. PubMed ID: 3077074
    [No Abstract]   [Full Text] [Related]  

  • 20. beta 2-Microglobulin amyloidosis: effect of ESRF treatment modality and dialysis membrane type.
    Van Ypersele de Strihou C
    Nephrol Dial Transplant; 1996; 11 Suppl 2():147-9. PubMed ID: 8804017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.